Genmab announced it is terminating clinical development of acasunlimab, a bispecific antibody that had been advanced in collaboration with BioNTech until that partner exited last year. The company said it will wind down the Phase 3 program and reallocate resources, ending work on an asset intended for lung cancer. The decision highlights continued pipeline pruning across oncology as companies reassess bispecific strategies after partnership breakups and challenging data.